HUTCHMED (HCM) and Innovent Biologics said Tuesday that the new drug application for the combination of ELUNATE and TYVYT has been granted conditional approval in China for the treatment of certain patients with advanced endometrial cancer.
This follows the priority review status and breakthrough therapy designation granted by the National Medical Products Administration of China.
The approval was supported by data from the phase II study, FRUSICA-1, which showed objective response rate and disease control rate of 35.6% and 88.5% respectively.
The company further said that the combination treatment showed rapid on-set efficacy, with a median time to response of 1.6 months, and median progression-free survival and overall survival of 9.5 months and 21.3 months, respectively.
The company also plans to do a phase III confirmatory study of the combination treatment.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。